CANCER RES:系统性分析揭示肿瘤微环境中的免疫细胞相互作用

2017-03-22 wangzhe MedSci原创

随着免疫疗法的大量出现,不管是在各类癌症中癌还是在组织特异性中,都迫切需要了解肿瘤微环境中的免疫细胞相互作用。

随着免疫疗法的大量出现,不管是在各类癌症中癌还是在组织特异性中,都迫切需要了解肿瘤微环境中的免疫细胞相互作用。

多维度数据集的使用使得系统的方法能够在大量患者中解析这些相互作用,进一步促进了我们对患者的实体瘤免疫应答的理解。通过使用综合的方法,我们检测了来自癌症基因组图谱的23种肿瘤类型中不同免疫细胞亚群的浸润水平。通过这些数据,我们构建了一个渗透网络,揭示细胞溶解细胞和骨髓细胞在肿瘤微环境中的相互作用。通过整合患者的基因突变数据,我们发现突变与不同肿瘤类型之间的免疫浸润差异相关,而其他因素可能解释了源于相同组织的不同肿瘤之间的差异。在多种肿瘤类型中,我们发现CD8 + T细胞浸润的保护作用被巨噬细胞和其他骨髓细胞所调节,表明骨髓来源的抑制细胞参与肿瘤发展。

我们的研究结果说明了肿瘤微环境中不同免疫细胞类型之间的复杂相互作用,并表明这些相互作用在患者生存中起着重要作用。这些结果证明了在研究肿瘤免疫原性和免疫治疗反应的因素时区分不同个体免疫反应情况的重要性。

原始出处:

Varn F S, Wang Y, Mullins D W, et al. Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment[J]. Cancer Research, 2017, 77(6): 1271-1282.DOI: 10.1158/0008-5472.CAN-16-2490

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909195, encodeId=2d16190919502, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Oct 03 22:14:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016954, encodeId=f9d42016954b1, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Feb 19 07:14:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471526, encodeId=b37314e152636, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Mar 24 06:14:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909195, encodeId=2d16190919502, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Oct 03 22:14:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016954, encodeId=f9d42016954b1, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Feb 19 07:14:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471526, encodeId=b37314e152636, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Mar 24 06:14:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909195, encodeId=2d16190919502, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Oct 03 22:14:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016954, encodeId=f9d42016954b1, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Feb 19 07:14:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471526, encodeId=b37314e152636, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Mar 24 06:14:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-24 ylz8405